Evidence map›Paper›PMID 33340067›Full record

ReviewDer Radiologe2021

[Imaging: The oncologist's perspective].

S Fuxius

Abstract readReview
PubMed Publisher
In one paragraph

Review in Der Radiologe, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

S FuxiusOnkologische Schwerpunktpraxis Heidelberg, Kurfürstenanlage 34, 60115, Heidelberg, Deutschland. stefanfuxius@gmx.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

clinical issueModern oncology has implemented several novel modalities, which increasingly warrant interdisciplinarity, dedicated imaging methods as well as intensive communication between imager and oncologists. STANDARD TREATMENT: The classical pillars of cancer treatment are surgery, radiotherapy, and chemotherapy. TREATMENT INNOVATIONS: Evidence-based oncology, radio-oncology, and surgery, individualized precision oncology, novel drug classes, immuno-oncology, minimally invasive diagnostic and treatment methods. DIAGNOSTIC WORK-UP: Standard imaging methods are undergoing constant innovation and are being supplemented by specific radiotracers that can be used for radionuclide therapy. Adapted response criteria are to be used in the context of targeted therapy or checkpoint inhibitors. PERFORMANCE AND ACHIEVEMENT: Modern cancer treatment enables improved tumor control. Due to its complexity, however, it increasingly warrants structured reporting and intense communication between imager and oncologists, to make best use of its potential.

Indexed as

NeoplasmsOncologistsRadiation OncologyHumansMedical OncologyPrecision MedicineCancer diagnosticsImmune therapyPrecision oncologyRadiation oncologyTargeted therapy

Identifiers

PMID33340067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.